Skeletal Muscle-Targeted LNP Development

Skeletal Muscle-Targeted LNP Development

We develop skeletal muscle-targeted LNPs through lipid modification and surface functionalization, providing end-to-end support from design and synthesis to formulation, characterization, and delivery evaluation.

Skeletal muscle-targeted LNPs are engineered to improve the delivery of nucleic acids to skeletal muscle tissue and muscle-associated cell populations. Unlike conventional LNPs that frequently accumulate in the liver, muscle-targeted formulations use tailored ionizable lipids, PEG-lipid architectures, or surface-displayed targeting ligands to modify tissue distribution and cellular uptake. These systems are being investigated for mRNA expression, gene silencing, genome editing, muscle regeneration, and metabolic disease research.

BOC Sciences provides integrated targeted LNP development, covering ionizable lipid screening, targeting ligand synthesis, surface functionalization, payload encapsulation, formulation optimization, and cellular and in vivo evaluation. We support the development of customized LNPs for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing research, with formulation strategies selected according to the intended muscle target and delivery route.

Lipid Nanoparticle Delivery to Skeletal Muscle DiagramSkeletal Muscle-Targeted Lipid Nanoparticle Illustration

BOC Sciences Skeletal Muscle-Targeted LNP Development Services

Our development services integrate lipid chemistry, surface engineering, nanoparticle formulation, and biological evaluation to address the challenges of skeletal muscle delivery. Projects can start with an existing LNP formulation, a specific targeting ligand, or a defined muscle-delivery objective. We customize the development scope according to payload properties, target-cell characteristics, and the intended administration route.

Muscle-Selective Lipid Design and Screening

We investigate how ionizable lipid structures and supporting lipid components influence muscle-cell interactions, intracellular delivery, and tissue distribution.

  • Ionizable Lipid Selection: Compare lipid headgroups, ionization behavior, hydrophobic tail number, branching, and linker structures to identify candidates for muscle-oriented delivery. Our LNP ionizable lipid optimization services support structure-guided screening.
  • Helper Lipid and Cholesterol Optimization: Adjust phospholipid identity, cholesterol content, and lipid ratios to maintain particle integrity, payload retention, and membrane interactions.
  • Structure-Performance Screening: Compare candidate lipid structures using particle characteristics, cellular uptake, reporter expression, and tissue-distribution readouts to identify formulation-dependent differences in muscle delivery.

Muscle-Targeting Ligand Engineering and Surface Display

We develop ligand-functionalized LNPs to improve interactions with selected muscle-associated cell populations. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together.

  • Peptide and Fusogen Engineering: Evaluate muscle-associated peptides and fusogenic protein components, including Myomerger-derived peptide designs and Myomaker-based surface functionalization, according to the intended delivery mechanism.
  • Antibody and Receptor-Binding Ligands: Explore antibody or antibody-fragment designs directed toward accessible muscle-associated surface markers, with target expression and species specificity considered during ligand selection.
  • Conjugation and Surface Display: Optimize linker chemistry, lipid anchors, coupling conditions, ligand density, and surface accessibility through appropriate nanoparticle conjugation services.

Payload-Compatible LNP Formulation and Process Optimization

We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended muscle-delivery application.

  • Payload Encapsulation: Optimize lipid-to-payload ratios, aqueous and organic phases, mixing conditions, and formulation pH for different nucleic acid structures through customized lipid nanoparticle formulation.
  • PEG-Lipid and Ligand Balance: Adjust PEG-lipid content, ligand incorporation, and surface composition to balance colloidal stability with muscle-cell accessibility.
  • Administration-Route Adaptation: Compare formulation requirements for local intramuscular injection, systemic intravenous administration, and regional limb perfusion, recognizing that each route presents different distribution and exposure conditions.
  • Process Parameter Optimization: Refine lipid concentration, mixing conditions, flow-rate ratios, and post-formulation processing through LNP process optimization.

Physicochemical, Cellular, and In Vivo Evaluation

We evaluate the physicochemical properties of candidate LNPs alongside muscle-cell delivery and tissue-level performance to identify whether formulation improvements translate into functional payload delivery.

  • Particle Characterization: Analyze particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and payload integrity using appropriate lipid nanoparticle characterization methods.
  • Muscle-Cell Uptake: Compare cellular association and internalization in selected myoblast, differentiating myocyte, and myotube models using nanoparticle cellular uptake testing.
  • Functional Delivery: Evaluate reporter expression, target-gene knockdown, protein expression, or genome-editing outcomes according to the payload and research objective.
  • Tissue-Level Evaluation: Compare skeletal muscle distribution, muscle-group accumulation, target-cell localization, and off-target organ exposure through nanoparticle cellular and in vivo evaluation.

Muscle-Targeting Strategies for Lipid Nanoparticles

Skeletal muscle-targeted LNPs can be developed through intrinsic lipid engineering or surface functionalization with muscle-associated peptides, fusogens, and antibodies. BOC Sciences supports lipid design and synthesis, ligand modification, LNP formulation, and delivery evaluation. The following strategies provide different options for developing muscle-targeted delivery systems.

Ionizable Lipid-Engineered Muscle-Selective LNPs

Muscle-selective LNPs can be developed by modifying ionizable lipid headgroups, hydrophobic tails, and linker structures to influence tissue distribution, membrane interactions, and endosomal escape. BOC Sciences supports customized ionizable lipid design, synthesis, structural screening, and LNP formulation.

  • Design Approach: Modify ionizable lipid headgroups, pKa, hydrophobic tail length, branching, asymmetry, and linker structures. Screen combinations with helper phospholipids, cholesterol, and PEG-lipids.
  • Use Scenarios: Develop mRNA-LNPs for muscle-localized protein expression, Cas9 mRNA/sgRNA delivery for genome-editing research, and muscle-associated gene modulation.

Research reference: iso-A11B5C1-based muscle-selective mRNA-LNPs (PNAS, 2023); A chemically defined ionizable-lipid LNP platform for intramuscular mRNA and CRISPR delivery (Nature Communications, 2021).

PEG-Lipid Architecture for Muscle-Selective Delivery

Muscle-selective delivery can be explored by modifying PEG-lipid hydrophobic anchors and linkers, which influence LNP surface properties, membrane interactions, and tissue distribution. BOC Sciences supports PEG-lipid design, synthesis, and composition optimization for muscle-oriented formulations.

  • Design Approach: Modify PEG-lipid hydrophobic anchor length, branching, asymmetry, and linker structure while controlling PEG molecular weight. Screen PEG-lipid molar fractions alongside ionizable and helper lipid compositions.
  • Use Scenarios: Develop mRNA-LNPs for intramuscular delivery, muscle-selective protein expression, gene-editing research, and muscle-associated mRNA immunization studies.

Research reference: Pr-182-BNT (P1B) LNPs containing branched, asymmetric-tail PEG-lipids for muscle-selective mRNA delivery (Small, 2026).

Peptide- and Fusogen-Functionalized LNPs

Muscle-associated peptides and fusogenic proteins can be displayed on LNP surfaces to enhance interactions with muscle-cell membranes or support fusion-related delivery. BOC Sciences supports peptide synthesis, protein-related surface engineering, lipid-anchor conjugation, and LNP functionalization.

  • Design Approach: Conjugate MyomP1 peptides to lipid anchors such as DSPE-PEG through suitable coupling chemistry. Alternatively, incorporate Myomaker onto LNP surfaces and optimize protein orientation, surface density, and lipid compatibility.
  • Use Scenarios: Develop LNPs for myoblast and myotube delivery, muscle differentiation and regeneration research, and mRNA or plasmid DNA expression studies.

Research reference: MyomP1-DSPE-PEG-functionalized LNPs for muscle-targeted gene delivery (Molecular Therapy – Nucleic Acids, 2026); Myomaker-functionalized LNPs for myogenic cell mRNA delivery (Advanced Functional Materials, 2026).

Antibody-Functionalized LNPs for Muscle-Associated Marker Recognition

Antibody-functionalized LNPs use surface-displayed recognition components to interact with selected muscle-associated markers and promote target-cell association. BOC Sciences supports antibody selection, conjugation chemistry, surface orientation optimization, and functionalized LNP development.

  • Design Approach: Select muscle-associated markers with experimentally confirmed extracellular accessibility, then design corresponding antibodies or antibody fragments. Optimize conjugation chemistry, spacer structure, ligand orientation, and surface density.
  • Use Scenarios: Explore miRNA delivery for skeletal muscle lipid-metabolism research and nucleic acid delivery to selected muscle-associated cell populations.

Research reference: miR-130a-loaded LNPs displaying five modified muscle-associated receptor-recognition components (Journal of Nanobiotechnology, 2025).

Which Muscle-Targeting Strategy Fits Your LNP Project?

Share your payload and target-cell requirements. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and develop a comparative formulation strategy.

Supported Payloads for Skeletal Muscle-Targeted LNPs

BOC Sciences develops muscle-targeted LNPs for the payload classes most frequently used in skeletal muscle delivery research. Each payload requires a matched loading strategy, particle design, and functional readout, and we help connect muscle-targeting design with payload-specific formulation requirements.

Payload TypeSupported Uses & Muscle-Targeted LNP Development ConsiderationsRequest Information
Muscle-Targeted LNP for mRNADesigned for reporter expression, protein replacement studies, and myotube-directed expression research. Development focuses on mRNA integrity, encapsulation efficiency, muscle-cell transfection, and muscle-versus-liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform.Inquiry
Muscle-Targeted LNP for siRNASuitable for gene-knockdown studies in myotube and myofiber-relevant models, including pathways involved in atrophy and metabolism. Development evaluates siRNA encapsulation, target silencing in muscle cells, and selectivity against hepatic uptake, drawing on our lipid nanoparticles for siRNA delivery experience.Inquiry
Muscle-Targeted LNP for Cas9 mRNA and sgRNAApplicable to genome-editing research in muscle models, where transient Cas9 expression and repeat-dosing capability are key advantages of LNP delivery. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in muscle cell models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities.Inquiry
Muscle-Targeted LNP for circRNA and saRNADesigned for payloads that require strong protection and sustained expression in muscle tissue. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in muscle-associated cell models, supported by our lipid nanoparticles for circRNA delivery platform.Inquiry
Muscle-Targeted LNP for ASOSuitable for splice-modifying and knockdown oligonucleotide research in muscle models, where oligonucleotide delivery to myofibers remains a major bottleneck. Development focuses on oligonucleotide loading, nuclear delivery, and uptake comparison across muscle cell populations, supported by our lipid nanoparticles for ASO delivery services.Inquiry
Muscle-Targeted LNP for Protein and PeptideApplicable to enzymes, signaling proteins, and peptide payloads intended for muscle-associated delivery research. Formulation work emphasizes mild loading conditions, aggregation control, and preserved biological activity, drawing on our protein encapsulation in LNPs experience.Inquiry
Muscle-Targeted LNP for Small MoleculeDesigned for hydrophobic, amphiphilic, or ionizable small molecules studied in muscle metabolism and atrophy research. We evaluate drug–lipid compatibility, loading method, retention during surface modification, and release behavior, supported by hydrophobic payload encapsulation in LNPs.Inquiry
Muscle-Targeted LNP for Fluorescent and Tracking LabelsSupports labeled particles used to map muscle-associated uptake, intracellular localization, and in vivo distribution trends across muscle groups, enabled by our tracking-labeled lipid nanoparticles capabilities.Inquiry
Muscle-Targeted LNP for Custom PayloadDeveloped for unusual payloads, co-delivery systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, muscle-targeting modification route, particle stability, and delivery performance in the agreed muscle cell models.Inquiry
Need a Muscle-Targeted LNP for Your Specific Payload?

Tell us your payload, target muscle group, and delivery goal, and BOC Sciences will propose a muscle-targeting strategy that fits your project.

Our Skeletal Muscle-Targeted LNP Development Workflow

Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as formulation and biological evidence becomes available.

Project requirement discussion

1Define the Target Muscle, Cell Population, and Payload

We review the payload class, target muscle group, intended cell population—mature myofibers, myoblasts, or satellite-cell-associated models—baseline LNP formulation if available, and desired biological readouts. These inputs define the starting materials, comparator models, and the screening plan.

Lipid composition and targeting architecture selection

2Select Lipid Composition and Targeting Architecture

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and PEG-lipid architectures, then select the targeting layer—lipid-intrinsic selectivity, peptide or fusogen display, or antibody orientation. Ratios are optimized through structured LNP lipid ratio optimization services, and each design includes matched non-targeted control LNPs.

LNP formulation and characterization

3Formulate and Characterize Candidate LNPs

Candidates are prepared under controlled mixing conditions and compared for particle size, PDI, zeta potential, ligand density, and payload retention. During LNP process optimization, we adjust composition, ligand input, purification, and buffer exchange, then advance only candidates that meet agreed particle-attribute thresholds.

Cellular and in vivo muscle delivery evaluation

4Evaluate Cellular Uptake and In Vivo Muscle Delivery

Selected candidates are evaluated in muscle cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression or gene knockdown. Combined nanoparticle cellular & in vivo evaluation then compares muscle-associated delivery against hepatic and splenic accumulation. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.

What Muscle-Targeted LNP Development Challenges Do We Solve?

A muscle-targeted LNP may be well characterized chemically yet still deliver mostly to the liver or transfect muscle cells inefficiently. We investigate formulation and biological factors together and use matched comparison studies to identify the step limiting performance.

✔ Hepatic Accumulation and Off-Target Organ Exposure

ApoE adsorption and LDL receptor-mediated uptake draw conventional LNPs into the liver, leaving little payload for muscle tissue. We compare ionizable lipid structures, PEG-lipid densities, and helper lipid balances to shift biodistribution, and quantify the muscle-to-liver delivery ratio for every candidate rather than relying on total expression data.

✔ Limited Vascular Transport and Muscle Tissue Penetration

The continuous endothelium of muscle vasculature and the dense extracellular matrix around myofibers restrict particle access. We tune particle size, surface charge, and PEG architecture within ranges compatible with tissue penetration, and verify the effects directly using uptake and distribution measurements instead of assuming that smaller particles always deliver better.

✔ Uneven Distribution Across Muscle Groups and Target Cell Populations

Delivery can differ widely between muscle groups and between myofibers and satellite-cell-associated populations. We use labeled particles and compartment-aware readouts to map where payload expression actually occurs, then adjust ligand density, composition, and administration-compatible design variables to reduce variability across the intended cell populations.

✔ Ligand Accessibility, Formulation Stability, and Endosomal Escape

Surface ligands can be masked by PEG, destabilize the particle, or improve uptake without improving cytosolic payload availability. We measure ligand exposure alongside particle stability, compare intracellular localization with functional readouts, and apply LNP endosomal escape evaluation to identify post-uptake limitations before reformulating.

Facing Low Muscle Delivery or High Liver Accumulation?

Tell us about your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.

Applications of Skeletal Muscle-Targeted LNPs

Skeletal muscle-targeted LNPs offer opportunities for nucleic acid delivery in genetic muscle disorders, muscle wasting, metabolic dysfunction, and tissue repair. BOC Sciences supports customized LNP development for these applications, including payload selection, lipid and ligand engineering, formulation optimization, and functional delivery evaluation.

01

Hereditary Muscular Dystrophy Research

  • Duchenne Muscular Dystrophy (DMD): Develop LNPs carrying Cas9 mRNA and guide RNA for dystrophin gene editing, or explore micro-dystrophin mRNA as a protein-expression payload. LNP-mediated CRISPR delivery has demonstrated dystrophin restoration in mouse models (Nature Communications, 2021).
  • Other Muscular Dystrophies: Explore gene-editing LNPs for limb-girdle muscular dystrophy (LGMD), including SORT-LNP delivery of TCAP-editing components in an LGMDR7 mouse model (Molecular Therapy, 2026). FSHD-related RNA delivery remains a potential development direction.
02

Muscle Atrophy, Cachexia, and Sarcopenia Research

  • Muscle Growth Regulation: Explore mRNA encoding follistatin or activin-pathway inhibitors to investigate myostatin signaling and muscle protein synthesis. Follistatin mRNA-loaded LNPs have been studied in cancer-associated cachexia, although that work did not establish muscle-targeted delivery (Small, 2022).
  • Muscle Maintenance: Investigate mRNA encoding IGF-1 pathway components and other myogenic regulators. Myomaker-functionalized LNPs provide a research basis for mRNA delivery to differentiating muscle cells (Advanced Functional Materials, 2026).
03

Muscle Metabolism and Metabolic Disease Research

  • Muscle Lipid Metabolism: Develop miRNA- or siRNA-loaded LNPs to investigate lipid accumulation and metabolic regulation. Muscle-targeted miR-130a LNPs have been reported to reduce skeletal muscle lipid deposition in high-fat-diet mice (Journal of Nanobiotechnology, 2025).
  • Glucose Regulation and Protein Expression: Explore mRNA encoding PGC-1α or selected secreted metabolic factors to study mitochondrial activity, insulin sensitivity, and muscle-derived protein signaling. These remain payload-specific development opportunities requiring experimental evaluation.
04

Muscle Regeneration and Angiogenesis Research

  • Ischemic Muscle Repair: Develop LNPs carrying SDF-1α or VEGF-A mRNA to investigate angiogenesis and vascular recovery. Intramuscular SDF-1α mRNA-LNP delivery has been studied in mouse hindlimb ischemia models (Angiogenesis, 2025).
  • Volumetric Muscle Loss and Tissue Repair: Explore regenerative mRNA-LNP formulations carrying NAMPT and other tissue-repair factors, including localized hydrogel delivery. NAMPT mRNA-LNP hydrogels have been investigated in a rat muscle-injury model (Journal of Controlled Release, 2025).
Develop a Skeletal Muscle LNP for Your Research Application

Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate skeletal muscle-targeted LNPs tailored to your project.

Why Choose BOC Sciences for Skeletal Muscle-Targeted LNP Development?

Advanced Muscle-Targeted Lipid Design Expertise

We connect ionizable lipid structure, helper lipid balance, and PEG architecture to biodistribution outcomes, helping teams move beyond liver-tropic default formulations with a defined, data-supported design logic.

Specialized Lipid Materials and Targeting Ligands

Our workflows cover myotropic lipid candidates, peptide and fusogen-derived ligands, cell-penetrating motifs, and antibody display, allowing the targeting layer to be matched to the payload and cell population rather than forced onto a fixed platform.

Comprehensive In Vitro and In Vivo Evaluation

Particle profiling, muscle-cell uptake and functional readouts, and in vivo distribution studies are combined in one program, so that formulation changes can be interpreted against both cellular and tissue-level delivery data.

Rapid Project Response and Development Iteration

Screening campaigns are organized around parallel candidate comparison with agreed endpoints, giving teams fast, interpretable feedback on which design variable to adjust in the next iteration.

End-to-End Skeletal Muscle LNP Development Services

From ligand selection and lipid synthesis to formulation, characterization, and delivery evaluation, the full development chain is handled within one integrated plan, reducing the disconnect between targeting chemistry and particle performance.

FAQs

What makes an LNP skeletal muscle-targeted?

Skeletal muscle-targeted LNPs are designed to improve nucleic acid delivery to skeletal muscle tissues and specific muscle-associated cell populations. Unlike conventional LNPs that often exhibit substantial hepatic accumulation, muscle-targeted systems use modified ionizable lipids, optimized PEG-lipid architectures, or surface-displayed targeting components to influence tissue distribution and cellular uptake. Their targeting performance depends on lipid composition, particle properties, administration route, and the biological characteristics of the intended muscle target.

Several approaches can be explored to improve skeletal muscle delivery. Ionizable lipid engineering modifies lipid headgroups and hydrophobic tails to influence tissue distribution and intracellular release. PEG-lipid structural optimization can alter particle interactions and muscle tropism. Surface functionalization with muscle-associated peptides, fusogenic proteins, or antibodies provides additional opportunities for cellular recognition. These approaches can be investigated individually or combined, depending on the target cell population, payload, and intended administration route.

Skeletal muscle-targeted LNPs can be developed for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing components such as Cas9 mRNA and guide RNA. Potential applications include protein expression, gene silencing, genetic modification, and regulation of muscle-associated metabolic pathways. Other payloads, including antisense oligonucleotides, proteins, and selected small molecules, can also be explored. The appropriate formulation depends on payload structure, loading requirements, intracellular delivery mechanisms, and the intended biological readout.

Evaluation generally combines physicochemical characterization, cellular uptake studies, functional payload assessment, and tissue-level distribution analysis. Particle size, PDI, zeta potential, morphology, encapsulation efficiency, and payload integrity are examined first. Cellular studies can compare uptake and functional delivery in myoblasts, differentiating myocytes, and myotubes. Where appropriate, studies investigate muscle accumulation, distribution across different muscle groups, target-cell localization, and off-target organ exposure. Results are interpreted together to distinguish particle accumulation from productive payload delivery.

Yes. BOC Sciences provides customized skeletal muscle-targeted LNP development, covering ionizable lipid design and synthesis, PEG-lipid optimization, targeting peptide or antibody functionalization, payload encapsulation, and formulation development. We can also support physicochemical characterization, muscle-cell uptake studies, functional delivery assessment, and distribution evaluation. Based on your intended application, target muscle, payload, and administration route, our team can help select suitable design strategies and establish a project-specific development and evaluation plan.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code